Market Cap 107.86M
Revenue (ttm) 1.12M
Net Income (ttm) -11.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -997.32%
Debt to Equity Ratio 0.00
Volume 2,092,300
Avg Vol 685,542
Day's Range N/A - N/A
Shares Out 45.13M
Stochastic %K 85%
Beta 1.12
Analysts Strong Sell
Price Target $7.12

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 284 4433
Fax: 650 397 4433
Address:
2570 West El Camino Real, Suite 320, Mountain View, United States
Wolfietrader
Wolfietrader Sep. 4 at 9:00 PM
$RNXT up 61% this week. Nice.
0 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Sep. 4 at 7:30 PM
$RNXT bull flag?
0 · Reply
atreus57
atreus57 Sep. 4 at 7:22 PM
$RNXT next-week setup looks strongly bullish. The most important signal today was the violent rejection of the ~$2.10 area. Sellers pushed it down, buyers immediately absorbed the supply, and price recovered back into the prior breakout structure. That is exactly what strong demand looks like. Technically: $2.10 = major demand confirmation $2.30-$2.40 = pivot/reclaim zone $2.59 = 52W breakout trigger Above $2.59 = price discovery / $3+ becomes realistic After running from ~$1.30 to $2.59, consolidation is healthy and necessary. The fact that $2.10 was rejected so aggressively suggests buyers are waiting underneath rather than abandoning the move. Fundamentals remain intact, liquidity has expanded dramatically, and management presents Sept. 14. My probability-weighted view: upside continuation next week is favored over a breakdown, with significant asymmetry if $2.59 falls. $RNXT
0 · Reply
tommy45
tommy45 Sep. 4 at 6:36 PM
$RNXT checking in bought another 10k today guys see next week gl
0 · Reply
atreus57
atreus57 Sep. 4 at 5:23 PM
$RNXT technical structure remains bullish. After expanding from $1.67 → $2.59 on massive volume, price is now compressing around $2.30-$2.40 while volume normalizes. That is textbook post-breakout consolidation, not confirmed distribution. Key structure: $2.28 = immediate demand zone $2.14 = major breakout support $1.93-$2.00 = former resistance / deep support $2.59 = breakout trigger As long as RNXT holds the $2.14-$2.28 structure, the higher-high/higher-low sequence remains intact. Bull case: hold $2.30 → reclaim $2.50 → break $2.59 → price discovery toward $2.80-$3.00+. Fundamentals are still advancing, and management presents Sept. 14. High-volume expansion + lower-volume consolidation + support above former resistance = bullish continuation setup. $RNXT
0 · Reply
LONGTERM123
LONGTERM123 Sep. 4 at 5:14 PM
$RNXT investors we will be opening up a short position later today. over value stock that we see heading back to $1
0 · Reply
atreus57
atreus57 Sep. 4 at 5:00 PM
$RNXT looks like healthy consolidation after a major breakout, not trend failure. Stocks don’t move straight up. After a fast run, price needs time to absorb profit-taking, warrant-related supply and new buyers. The important part: RNXT is still holding well above the old $1.75-$1.93 resistance/warrant zone. Meanwhile the growth thesis remains intact: • RenovoCath revenue accelerating • active centers expanding • repeat orders developing • Q3 expected above Q2 • Phase III enrollment complete • readout path intact Consolidation + improving fundamentals is exactly what you want before the next leg. If $RNXT keeps building support above $2 and eventually clears the recent high, I expect the growth regime to continue. Bullish.
0 · Reply
atreus57
atreus57 Sep. 4 at 4:54 PM
$RNXT This is a nice and calm long term investment but I am pretty sure this will grow above 3 in a matter of weeks to months and by next year it may reach 5-7...
0 · Reply
LONGTERM123
LONGTERM123 Sep. 4 at 4:51 PM
$RNXT investors pump and dump stock over value and over hype stock will be shorted next week back to $1 you been warn take profit ASAP.
0 · Reply
atreus57
atreus57 Sep. 4 at 4:40 PM
$RNXT you know it's pretty much unavoidable that this will reach 4-5 in a matter of months to a year...
0 · Reply
Latest News on RNXT
RenovoRx regains compliance with Nasdaq

2026-08-21T12:45:28.000Z - 16 days ago

RenovoRx regains compliance with Nasdaq


RenovoRx reports Q2 EPS (5c), consensus (8c)

2026-08-17T08:44:19.000Z - 21 days ago

RenovoRx reports Q2 EPS (5c), consensus (8c)


RenovoRx Transcript: Status update

Aug 13, 2026, 1:30 PM EDT - 24 days ago

RenovoRx Transcript: Status update


RenovoRx Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 25 days ago

RenovoRx Earnings Call Transcript: Q2 2026


RenovoRx Earnings release: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 25 days ago

RenovoRx Earnings release: Q2 2026


RenovoRx Quarterly report: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 25 days ago

RenovoRx Quarterly report: Q2 2026


RenovoRx completes enrollment in TIGeR-PaC trial

2026-08-11T12:50:37.000Z - 26 days ago

RenovoRx completes enrollment in TIGeR-PaC trial


RenovoRx Slides: Investor presentation

Jun 15, 2026, 7:00 AM EDT - 2 months ago

RenovoRx Slides: Investor presentation


RenovoRx announces FDA Orphan Drug Designation for oxaliplatin

2026-05-28T14:40:48.000Z - 3 months ago

RenovoRx announces FDA Orphan Drug Designation for oxaliplatin


RenovoRx announces pharmacokinetic data using TAMP platform

2026-05-26T14:34:27.000Z - 3 months ago

RenovoRx announces pharmacokinetic data using TAMP platform


RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)

2026-05-14T21:08:58.000Z - 3 months ago

RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)


RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M

2026-05-14T21:02:36.000Z - 3 months ago

RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M


RenovoRx Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

RenovoRx Earnings Call Transcript: Q1 2026


RenovoRx Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

RenovoRx Earnings release: Q1 2026


RenovoRx Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

RenovoRx Quarterly report: Q1 2026


RenovoRx Slides: Investor presentation

May 4, 2026, 7:00 AM EDT - 4 months ago

RenovoRx Slides: Investor presentation


RenovoRx Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

RenovoRx Proxy statement: Proxy filing


RenovoRx files to sell 8.44M shares of common stock for holders

2026-04-16T21:15:42.000Z - 4 months ago

RenovoRx files to sell 8.44M shares of common stock for holders


RenovoRx Registration statement: Registration filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

RenovoRx Registration statement: Registration filing


RenovoRx Earnings Call Transcript: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 5 months ago

RenovoRx Earnings Call Transcript: Q4 2025


RenovoRx Annual report: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 5 months ago

RenovoRx Annual report: Q4 2025


RenovoRx Earnings release: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 5 months ago

RenovoRx Earnings release: Q4 2025


RenovoRx prices 10.6M shares at 93.8c in private placement

2026-03-18T12:45:53.000Z - 5 months ago

RenovoRx prices 10.6M shares at 93.8c in private placement


RenovoRx Announces $10 Million at Market Private Placement

Mar 18, 2026, 8:35 AM EDT - 5 months ago

RenovoRx Announces $10 Million at Market Private Placement


RenovoRx advances RenovoCath adoption at U.S. cancer centers

2026-02-27T14:01:24.000Z - 6 months ago

RenovoRx advances RenovoCath adoption at U.S. cancer centers


RenovoRx establishes RenovoCath Medical Advisory Board

2026-02-10T13:47:32.000Z - 6 months ago

RenovoRx establishes RenovoCath Medical Advisory Board


RenovoRx Establishes RenovoCath® Medical Advisory Board

Feb 10, 2026, 8:30 AM EST - 6 months ago

RenovoRx Establishes RenovoCath® Medical Advisory Board


RenovoRx appoints Voll as Chief Financial Officer

2026-02-05T13:40:28.000Z - 7 months ago

RenovoRx appoints Voll as Chief Financial Officer


RenovoRx announces new clinical data on TAMP therapy platform

2026-02-04T13:36:25.000Z - 7 months ago

RenovoRx announces new clinical data on TAMP therapy platform


RenovoRx Transcript: IAccess Alpha Virtual MicroCap Conference

Dec 9, 2025, 12:30 PM EST - 9 months ago

RenovoRx Transcript: IAccess Alpha Virtual MicroCap Conference


RenovoRx Transcript: AGP Emerging AgBiotech/Bio-Solutions

Nov 20, 2025, 2:00 PM EST - 9 months ago

RenovoRx Transcript: AGP Emerging AgBiotech/Bio-Solutions


RenovoRx Registration statement: Registration Filing

Nov 14, 2025, 7:00 AM EST - 9 months ago

RenovoRx Registration statement: Registration Filing


RenovoRx Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

RenovoRx Earnings Call Transcript: Q3 2025


RenovoRx Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

RenovoRx Quarterly report: Q3 2025


RenovoRx Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

RenovoRx Earnings release: Q3 2025


RenovoRx Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

RenovoRx Earnings Call Transcript: Q2 2025


RenovoRx Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

RenovoRx Quarterly report: Q2 2025


RenovoRx Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

RenovoRx Earnings release: Q2 2025


RenovoRx Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

RenovoRx Earnings Call Transcript: Q1 2025


RenovoRx Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

RenovoRx Quarterly report: Q1 2025


RenovoRx Earnings release: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

RenovoRx Earnings release: Q1 2025


Wolfietrader
Wolfietrader Sep. 4 at 9:00 PM
$RNXT up 61% this week. Nice.
0 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Sep. 4 at 7:30 PM
$RNXT bull flag?
0 · Reply
atreus57
atreus57 Sep. 4 at 7:22 PM
$RNXT next-week setup looks strongly bullish. The most important signal today was the violent rejection of the ~$2.10 area. Sellers pushed it down, buyers immediately absorbed the supply, and price recovered back into the prior breakout structure. That is exactly what strong demand looks like. Technically: $2.10 = major demand confirmation $2.30-$2.40 = pivot/reclaim zone $2.59 = 52W breakout trigger Above $2.59 = price discovery / $3+ becomes realistic After running from ~$1.30 to $2.59, consolidation is healthy and necessary. The fact that $2.10 was rejected so aggressively suggests buyers are waiting underneath rather than abandoning the move. Fundamentals remain intact, liquidity has expanded dramatically, and management presents Sept. 14. My probability-weighted view: upside continuation next week is favored over a breakdown, with significant asymmetry if $2.59 falls. $RNXT
0 · Reply
tommy45
tommy45 Sep. 4 at 6:36 PM
$RNXT checking in bought another 10k today guys see next week gl
0 · Reply
atreus57
atreus57 Sep. 4 at 5:23 PM
$RNXT technical structure remains bullish. After expanding from $1.67 → $2.59 on massive volume, price is now compressing around $2.30-$2.40 while volume normalizes. That is textbook post-breakout consolidation, not confirmed distribution. Key structure: $2.28 = immediate demand zone $2.14 = major breakout support $1.93-$2.00 = former resistance / deep support $2.59 = breakout trigger As long as RNXT holds the $2.14-$2.28 structure, the higher-high/higher-low sequence remains intact. Bull case: hold $2.30 → reclaim $2.50 → break $2.59 → price discovery toward $2.80-$3.00+. Fundamentals are still advancing, and management presents Sept. 14. High-volume expansion + lower-volume consolidation + support above former resistance = bullish continuation setup. $RNXT
0 · Reply
LONGTERM123
LONGTERM123 Sep. 4 at 5:14 PM
$RNXT investors we will be opening up a short position later today. over value stock that we see heading back to $1
0 · Reply
atreus57
atreus57 Sep. 4 at 5:00 PM
$RNXT looks like healthy consolidation after a major breakout, not trend failure. Stocks don’t move straight up. After a fast run, price needs time to absorb profit-taking, warrant-related supply and new buyers. The important part: RNXT is still holding well above the old $1.75-$1.93 resistance/warrant zone. Meanwhile the growth thesis remains intact: • RenovoCath revenue accelerating • active centers expanding • repeat orders developing • Q3 expected above Q2 • Phase III enrollment complete • readout path intact Consolidation + improving fundamentals is exactly what you want before the next leg. If $RNXT keeps building support above $2 and eventually clears the recent high, I expect the growth regime to continue. Bullish.
0 · Reply
atreus57
atreus57 Sep. 4 at 4:54 PM
$RNXT This is a nice and calm long term investment but I am pretty sure this will grow above 3 in a matter of weeks to months and by next year it may reach 5-7...
0 · Reply
LONGTERM123
LONGTERM123 Sep. 4 at 4:51 PM
$RNXT investors pump and dump stock over value and over hype stock will be shorted next week back to $1 you been warn take profit ASAP.
0 · Reply
atreus57
atreus57 Sep. 4 at 4:40 PM
$RNXT you know it's pretty much unavoidable that this will reach 4-5 in a matter of months to a year...
0 · Reply
atreus57
atreus57 Sep. 4 at 4:36 PM
$RNXT we will see it above 7 at some point in the future but in a matter of weeks I see it at or above 3
0 · Reply
atreus57
atreus57 Sep. 4 at 4:35 PM
$RNXT this will clearly go to 5 very soon
0 · Reply
LONGTERM123
LONGTERM123 Sep. 4 at 4:08 PM
$RNXT investors main group of pumpers will open a huge short position to drive this down next week to $1 you have been warn about this pure pump and dump stock.
0 · Reply
LONGTERM123
LONGTERM123 Sep. 4 at 4:02 PM
$RNXT investors price will drop to $1.50 by next week pump over these groups will short this now . investors no news coming here about any treatment just smoke and mirrors with a penny stock.
0 · Reply
LONGTERM123
LONGTERM123 Sep. 4 at 3:43 PM
$RNXT investors a penny stock once below $1 now at over value levels should be around those levels now. pump groups been pumping this for over a month now with swing trading next down push will put this right back below $2 soon soon the same group will short it back to around $1 no new coming until spring of 2027 or later here .
0 · Reply
LONGTERM123
LONGTERM123 Sep. 4 at 3:35 PM
$RNXT investors time to short this below $2 for good over hype stock that will have no real news until 2027 .
0 · Reply
atreus57
atreus57 Sep. 4 at 3:03 PM
$RNXT bullish thesis remains intact. This isn’t just momentum anymore: RenovoCath revenue is accelerating, Phase III enrollment is complete, Nasdaq risk is resolved, PK/PD data support the TAMP mechanism, and the stock has now broken through the old $1.75-$1.93 warrant zone on huge volume. Technical roadmap: $2.00-$2.10 = major support $2.59 = breakout level $2.59 = $3.00-$3.50 becomes realistic Strong Q3 commercial data = potential $4+ re-rating My view: $3-$3.50 is achievable near term if the breakout confirms, with $4-$5 plausible into 2027 as commercialization scales and TIGeR-PaC approaches readout. The key is that RNXT is transitioning from “distressed microcap” valuation toward “commercial + Phase III optionality.” Still early. $RNXT $XBI $IBB
1 · Reply
atreus57
atreus57 Sep. 4 at 3:00 PM
$RNXT massive growth coming… very bullish…
0 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Sep. 4 at 2:42 PM
$RNXT and just like that, the volume disappeared
2 · Reply
HypnoTrader
HypnoTrader Sep. 4 at 2:31 PM
$RNXT still betting either a warrant incentive or a brand new dilution after the close today. Like little kids, after they make a mess they just want to walk away and shut the door. They have no prospects for anything in any foreseable future and they will try to keep at least one year to 18 months of cash in the bank at all times. These people have yachts, summer houses and private schools to pay for. They cannot afford to live hand to mouth. They need to be sure their lifestyle will continue....
0 · Reply
BA777
BA777 Sep. 4 at 2:20 PM
$RNXT Bids are stacking nice.
0 · Reply
atreus57
atreus57 Sep. 4 at 1:10 PM
$RNXT technical setup still looks BULLISH after a massive breakout. The key isn’t that it went straight up—it’s that volume exploded as price cleared the old $1.75-$1.93 warrant/resistance zone and has stayed above it. Aug 31: $1.93 Sep 1: $2.11 Sep 2: $2.52 Sep 3: $2.37 on ~3.8M volume That looks like high-volume consolidation, not a broken trend. Key levels: $2.00-$2.10 = major support $2.35-$2.40 = current pivot $2.59 = breakout trigger / 52W high A clean break and close above $2.59 could open $3+. Best part: former resistance is now below price, liquidity has exploded, and management presents at H.C. Wainwright Sept 14. Bulls don’t need a straight line. Holding $2+ after this move = strength. $RNXT
1 · Reply